

Mouse Anti-Mesothelin [MSLN/2131]: MC0207, MC0207RTU7

Intended Use: For Research Use Only

Description: The mesothelin gene encodes a 69-kDa precursor protein that is processed to a 40-kDa glycosylphosphatidylinositol (GPI)-anchored protein, the mature mesothelin, present on the cell surface. Its biological function is not known, but recent studies have shown that it forms a strong and specific complex with MUC16; a binding which has been suggested to be the basis of ovarian cancer metastasis. Mesothelin is present on normal mesothelial cells lining the pleura, peritoneum, and pericardium. In tumors, overexpression of Mesothelin has been observed in mesotheliomas, and other tumors including ovarian, pancreatic carcinomas, and cholangiocarcinoma. By using immunotoxin targeting immunotherapy, mesothelin has also been reported as a new therapeutic target in various types of cancers, such as human cholangiocarcinoma.

Specifications


| | |
|---------------|---|
| Clone: | MSLN/2131 |
| Source: | Mouse |
| Isotype: | IgG2b/k |
| Reactivity: | Human, mouse, rat |
| Localization: | Membrane, secreted |
| Formulation: | Purified antibody in 0.2% BSA and 15mM sodium azide (NaN ₃) |
| Storage: | Store at 2°- 8°C |
| Applications: | IHC |
| Package: | |

| Description | Catalog No. | Size |
|-------------------------------------|-------------|------|
| Mesothelin [MSLN/2131] Concentrated | MC0207 | 1 ml |
| Mesothelin [MSLN/2131] Prediluted | MC0207RTU7 | 7 ml |

IHC Procedure*

| | |
|---------------------------|--|
| Positive Control Tissue: | Mesothelioma |
| Concentrated Dilution: | 50-200 |
| Pretreatment: | Citrate pH6.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C |
| Incubation Time and Temp: | 30-60 minutes @ RT |
| Detection: | Refer to the detection system manual |

* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-Mesothelin using DAB

References:

1. Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases. Tandon RT et al. Arch Pathol Lab Med. 2018.
2. Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy. Hanaoka T et al. Mol Diagn Ther. 2017.
3. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Golfier S et al. Mol Cancer Ther. 2014.

Doc. 100-MC0207
Rev. A